Receive The Newest Study Notifications

FibroGen, Inc., (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with unresectable locally advanced pancreatic cancer (LAPC). “Patients with unresectable locally advanced pancreatic cancer...

REDWOOD SHORES, Calif., Oct. 23, 2019 /PRNewswire/ -- Oracle Health Sciences, a leader in eClinical technology and Phlexglobal, pioneers in the provision of Trial Master File (TMF) technology and services for the global life sciences industry, have announced enhanced...

 BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has enrolled its first patient in a Phase 3, Study 106, clinical trial with its lead...

$90 million award expected from the National Institute of Aging and the National Heart, Lung, & Blood Institute to fund largest pragmatic trial with placebo-controlled drug assignment to date In the first statin trial with a non-cardiovascular primary outcome,...

Sofinnova Partners – Life sciences-focused venture capital firm based in Paris, closed its latest fund, Sofinnova Capital IX, oversubscribed at €333 million. The firm now has more than €2B under management with more than €1B raised in the last four years across its...

Third first-in-human cancer treatment trial to open at U of M in last two months MINNEAPOLIS, MN- October 21, 2019 - A new cancer clinical trial has opened at the M Health Fairview University of Minnesota Medical Center that leverages the groundbreaking research on...

Mark Terry of BioSpace writes: Pfizer announced results from its Phase III clinical trial, JADE MONO-1, of abrocitinib in moderate to severe atopic dermatitis. The drug met all the co-primary and key secondary endpoints related to skin clearance and itch relief...

Key Points Question  At birth, are the risks of sensitization to cow’s milk formula and food allergy decreased by avoiding or by supplementing with cow’s milk formula? Findings  In this randomized clinical trial involving 312 newborns, risks of sensitization to cow’s...

NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient...

-- Late-breaker abstract, "A North American Randomized Controlled Trial (RCT) of Terlipressin plus Albumin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)" -- STAINES-UPON-THAMES, United Kingdom, Oct. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a...

TORONTO, ON / ACCESSWIRE / October 21, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2b clinical trial evaluating the company's lead product candidate, EB01, as...

Pooled analyses of the Phase 3 CAMP studies in molluscum contagiosum showed VP-102 achieved statistically significantly higher rate of complete lesion clearance and percentage of subjects with > 75% and > 90% lesion clearance rates over the course of therapy...

Trial to support anticipated BLA submission in 1H 2022 Lausanne, Switzerland, October 17, 2019 - ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (ADCs) for...

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the enrollment and first treatment of a patient with newly diagnosed brain cancer in a...

D-PLEX100 Administration into the Surgical Site Led to Statistically Significant Reduction in Infections Compared to Standard of Care Alone Company Intends to Hold End of Phase 2 Meeting with FDA and Subsequently Submit an IND to Conduct a Phase 3 Clinical Trial in...

Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, today announced dosing of the first patient in a Phase 1 clinical trial in solid tumors evaluating AMV564, a CD33/CD3 T cell engager that...

- Investigational compound BI ENaC inhibitor delivered twice daily via the Respimat®, a handheld inhaler RIDGEFIELD, Conn., Oct. 16, 2019 /PRNewswire/ -- Boehringer Ingelheim today announced the first patient enrolled in its Phase II clinical trial BALANCE-CF™ 1 to...

Clinical trials not only facilitate new drug development, but they can provide care to patients who desperately need more options, such as those with cancer. While trials may be listed online in readily accessible databases, such as those listed...

A new clinical trial will test whether cannabidiol (CBD) products are safe to use as a treatment for Parkinson disease (PD)-related psychosis, MD Magazine reported. According to the article, a team of researchers will be conducting a phase 2 clinical trial testing the...

First participants enrolled in pivotal Phase 3 clinical trial of NanoFlu Top-line clinical data expected in the first quarter of 2020 Phase 3 results expected to support a future BLA and licensure of NanoFlu using the FDA’s accelerated approval pathway GAITHERSBURG,...